The Experts below are selected from a list of 59709 Experts worldwide ranked by ideXlab platform
Xin Wei Wang - One of the best experts on this subject based on the ideXlab platform.
-
a unique metastasis Gene Signature enables prediction of tumor relapse in early stage hepatocellular carcinoma patients
Cancer Research, 2010Co-Authors: Stephanie Roessler, Anuradha Budhu, Marshonna Forgues, Qing Hai Ye, Snorri S Thorgeirsson, Zhaoyou Tang, Xin Wei WangAbstract:Metastasis-related recurrence often occurs in hepatocellular carcinoma (HCC) patients who receive curative therapies. At present, it is challenging to identify patients with high risk of recurrence, which would warrant additional therapies. In this study, we sought to analyze a recently developed metastasis-related Gene Signature for its utility in predicting HCC survival, using 2 independent cohorts consisting of a total of 386 patients who received radical resection. Cohort 1 contained 247 predominantly HBV-positive cases analyzed with an Affymetrix platform, whereas cohort 2 contained 139 cases with mixed etiology analyzed with the NCI Oligo Set microarray platform. We employed a survival risk prediction algorithm with training, test, and independent cross-validation strategies and found that the Gene Signature is predictive of overall and disease-free survival. Importantly, risk was significantly predicted independently of clinical characteristics and microarray platform. In addition, survival prediction was successful in patients with early disease, such as small (<5 cm in diameter) and solitary tumors, and the Signature predicted particularly well for early recurrence risk (<2 years), especially when combined with serum alpha fetoprotein or tumor staging. In conclusion, we have shown in 2 independent cohorts with mixed etiologies and ethnicity that the metastasis Gene Signature is a useful tool to predict HCC outcome, suggesting the General utility of this classifier. We recommend the use of this classifier as a molecular diagnostic test to assess the risk that an HCC patient will develop tumor relapse within 2 years after surgical resection, particularly for those with early-stage tumors and solitary presentation.
-
a unique metastasis Gene Signature enables prediction of tumor relapse in early stage hepatocellular carcinoma patients
Cancer Research, 2010Co-Authors: Stephanie Roessler, Anuradha Budhu, Marshonna Forgues, Qing Hai Ye, Snorri S Thorgeirsson, Zhaoyou Tang, Xin Wei WangAbstract:Metastasis-related recurrence often occurs in hepatocellular carcinoma (HCC) patients who receive curative therapies. At present, it is challenging to identify patients with high risk of recurrence, which would warrant additional therapies. In this study, we sought to analyze a recently developed metastasis-related Gene Signature for its utility in predicting HCC survival, using 2 independent cohorts consisting of a total of 386 patients who received radical resection. Cohort 1 contained 247 predominantly HBV-positive cases analyzed with an Affymetrix platform, whereas cohort 2 contained 139 cases with mixed etiology analyzed with the NCI Oligo Set microarray platform. We employed a survival risk prediction algorithm with training, test, and independent cross-validation strategies and found that the Gene Signature is predictive of overall and disease-free survival. Importantly, risk was significantly predicted independently of clinical characteristics and microarray platform. In addition, survival prediction was successful in patients with early disease, such as small ( Cancer Res; 70(24); 10202–12. ©2010 AACR .
Jeanyves Pierga - One of the best experts on this subject based on the ideXlab platform.
-
a Gene Signature of chemo immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
Journal of Clinical Oncology, 2017Co-Authors: Mohamedamine Bayar, Carmen Criscitiello, Giuseppe Curigliano, W F Symmans, Christine Desmedt, Herve Bonnefoi, Bruno Valentin Sinn, Giancarlo Pruneri, Cecile Vicier, Jeanyves PiergaAbstract:575Background: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease after anthracycline-based neoadjuvant chemotherapy (NACT) is associated with a better prognosis. We aimed to develop a genomic Signature from pre-treatment samples to predict the extent of TILs after NACT, and then to test its prognostic value on survival. Methods: Using 99 pre-treatment samples (training set), we Generated a four-Gene Signature that predicts post-NACT TILs using the LASSO technique. Prognostic value of the Signature on survival was assessed on the training set (n=99) and then evaluated on an independent validation set including 185 patients with TNBC treated with NACT. Results: A four-Gene Signature, assessed on pre-treatment samples and combining the expression levels of HLF, CXCL13, SULT1E1, and GBP1 predicted the extent of lymphocytic infiltration after NACT. In a multivariate analysis performed on the training set, a one-unit increase in th...
-
70 Gene Signature as an aid to treatment decisions in early stage breast cancer
The New England Journal of Medicine, 2016Co-Authors: Fatima Cardoso, Laura Vant J Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, S Delaloge, Jeanyves Pierga, E Brain, Sylvain Causeret, Mauro DelorenziAbstract:BackgroundThe 70-Gene Signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-Gene Signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy. MethodsIn this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-Gene Signature) and their clinical risk (using a modified version of Adjuvant! Online). Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy. In patients with discordant risk results, either the genomic risk or the clinical risk was used to determine the use of chemotherapy. The primary goal was to assess whether, among patients with high-risk clinical features and a low-risk Gene-expression profile who did not receive chemotherapy, the...
Kerby Shedden - One of the best experts on this subject based on the ideXlab platform.
-
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
The New England journal of medicine, 2007Co-Authors: Rui Liu, Xinhao Wang, Grace Y. Chen, Piero Dalerba, Austin L. Gurney, Timothy Hoey, Gavin Sherlock, John Lewicki, Kerby Shedden, Michael F. ClarkeAbstract:BACKGROUND Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS We compared the Gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed Genes were used to Generate a 186-Gene "invasiveness" Gene Signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS There was a significant association between the IGS and both overall and metastasis-free survival (P
-
the prognostic role of a Gene Signature from tumorigenic breast cancer cells
The New England Journal of Medicine, 2007Co-Authors: Rui Liu, Xinhao Wang, Grace Y. Chen, Piero Dalerba, Austin L. Gurney, Timothy Hoey, Gavin Sherlock, John Lewicki, Kerby SheddenAbstract:BACKGROUND Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS We compared the Gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed Genes were used to Generate a 186-Gene "invasiveness" Gene Signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) Signature. CONCLUSIONS The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This Genetic Signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR Signature in breast cancer.
Piero Dalerba - One of the best experts on this subject based on the ideXlab platform.
-
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
The New England journal of medicine, 2007Co-Authors: Rui Liu, Xinhao Wang, Grace Y. Chen, Piero Dalerba, Austin L. Gurney, Timothy Hoey, Gavin Sherlock, John Lewicki, Kerby Shedden, Michael F. ClarkeAbstract:BACKGROUND Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS We compared the Gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed Genes were used to Generate a 186-Gene "invasiveness" Gene Signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS There was a significant association between the IGS and both overall and metastasis-free survival (P
-
the prognostic role of a Gene Signature from tumorigenic breast cancer cells
The New England Journal of Medicine, 2007Co-Authors: Rui Liu, Xinhao Wang, Grace Y. Chen, Piero Dalerba, Austin L. Gurney, Timothy Hoey, Gavin Sherlock, John Lewicki, Kerby SheddenAbstract:BACKGROUND Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS We compared the Gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed Genes were used to Generate a 186-Gene "invasiveness" Gene Signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) Signature. CONCLUSIONS The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This Genetic Signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR Signature in breast cancer.
Stephanie Roessler - One of the best experts on this subject based on the ideXlab platform.
-
a unique metastasis Gene Signature enables prediction of tumor relapse in early stage hepatocellular carcinoma patients
Cancer Research, 2010Co-Authors: Stephanie Roessler, Anuradha Budhu, Marshonna Forgues, Qing Hai Ye, Snorri S Thorgeirsson, Zhaoyou Tang, Xin Wei WangAbstract:Metastasis-related recurrence often occurs in hepatocellular carcinoma (HCC) patients who receive curative therapies. At present, it is challenging to identify patients with high risk of recurrence, which would warrant additional therapies. In this study, we sought to analyze a recently developed metastasis-related Gene Signature for its utility in predicting HCC survival, using 2 independent cohorts consisting of a total of 386 patients who received radical resection. Cohort 1 contained 247 predominantly HBV-positive cases analyzed with an Affymetrix platform, whereas cohort 2 contained 139 cases with mixed etiology analyzed with the NCI Oligo Set microarray platform. We employed a survival risk prediction algorithm with training, test, and independent cross-validation strategies and found that the Gene Signature is predictive of overall and disease-free survival. Importantly, risk was significantly predicted independently of clinical characteristics and microarray platform. In addition, survival prediction was successful in patients with early disease, such as small (<5 cm in diameter) and solitary tumors, and the Signature predicted particularly well for early recurrence risk (<2 years), especially when combined with serum alpha fetoprotein or tumor staging. In conclusion, we have shown in 2 independent cohorts with mixed etiologies and ethnicity that the metastasis Gene Signature is a useful tool to predict HCC outcome, suggesting the General utility of this classifier. We recommend the use of this classifier as a molecular diagnostic test to assess the risk that an HCC patient will develop tumor relapse within 2 years after surgical resection, particularly for those with early-stage tumors and solitary presentation.
-
a unique metastasis Gene Signature enables prediction of tumor relapse in early stage hepatocellular carcinoma patients
Cancer Research, 2010Co-Authors: Stephanie Roessler, Anuradha Budhu, Marshonna Forgues, Qing Hai Ye, Snorri S Thorgeirsson, Zhaoyou Tang, Xin Wei WangAbstract:Metastasis-related recurrence often occurs in hepatocellular carcinoma (HCC) patients who receive curative therapies. At present, it is challenging to identify patients with high risk of recurrence, which would warrant additional therapies. In this study, we sought to analyze a recently developed metastasis-related Gene Signature for its utility in predicting HCC survival, using 2 independent cohorts consisting of a total of 386 patients who received radical resection. Cohort 1 contained 247 predominantly HBV-positive cases analyzed with an Affymetrix platform, whereas cohort 2 contained 139 cases with mixed etiology analyzed with the NCI Oligo Set microarray platform. We employed a survival risk prediction algorithm with training, test, and independent cross-validation strategies and found that the Gene Signature is predictive of overall and disease-free survival. Importantly, risk was significantly predicted independently of clinical characteristics and microarray platform. In addition, survival prediction was successful in patients with early disease, such as small ( Cancer Res; 70(24); 10202–12. ©2010 AACR .